Search a Conference through our dedicated search page

HIV Persistence: Pathogenesis and Eradication

20th March 2016 - 24th March 2016
Olympic Valley, United States


HIV Vaccines. Despite the clinical success of antiretroviral therapy (ART), every day there are more people newly infected with HIV than those initiating ART. The complexities of dispensing lifelong ART for HIV-infected individuals make it imperative to develop strategies for HIV eradication, or at least to strictly control the virus without daily therapy. The clearance of a retroviral infection is a herculean task and requires unraveling the mechanisms of viral persistence and host immune interactions. Further, ART does not appear to completely mitigate the impact of HIV infection on human health, and a better understanding of the overt and subtle immune pathologies induced by HIV infection is needed. Recent studies of early therapeutic interventions and HIV-resistant cellular therapies have provided new insights into the development of HIV eradication strategies. The meeting will focus on all aspects of HIV persistence and eradication that include: (1) The understanding of persistent HIV infection; (2) Innate defenses against retroviral infection; (3) The interplay of the host inflammatory response and HIV pathogenesis; and (4) Novel concepts for viral eradication. Special attention will be paid to progress in the development of model systems to study latent infection as well as strategies to eradicate it. Emphasis will be placed on new, unpublished findings that will highlight novel insights and creative strategies to develop effective control and eradication of HIV infection.

Related Fields